{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"description":"The objective response following KZR-261 defined as a best overall response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. A CR is defined as the disappearance of all target lesions and a PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of longest lesion diameters.","groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG008","title":"Dose 9"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG009","title":"Melanoma Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"The Response Evaluable Population is defined as all participants who received at least 1 dose of study treatment (KZR-261) and who have a baseline and at least 1 post-baseline anti-tumor response assessment.","reportingStatus":"POSTED","timeFrame":"20 months","title":"Objective Response (ORR) Following KZR-261","type":"SECONDARY","unitOfMeasure":"participants"}